In March 2022, Adam Steensberg became CEO of struggling Zealand Pharma and almost three years later to the day, the firm’s future looks far brighter with a promising pipeline and a multibillion dollar obesity deal secured with Roche.
Key Takeaways
- The just-announced Roche pact validates Zealand’s BD strategy
- It now wants to partner short bowel syndrome drug, glepaglutide, and obesity asset, dapaglutide
Speaking to Scrip after the Swiss giant agreed to pay a whopping $1.65bn upfront fee to co-develop and co-commercialize Zealand’s closely watched, potentially best-in-class therapy, petrelintide, Steensberg reflected on the progress made at the firm since he took up the post
